Literature DB >> 32601465

Mitral valve regurgitation: a disease with a wide spectrum of therapeutic options.

Benedetto Del Forno1, Michele De Bonis1, Eustachio Agricola2, Francesco Melillo2, Davide Schiavi1,3, Alessandro Castiglioni1, Matteo Montorfano4, Ottavio Alfieri5,6.   

Abstract

Over the past two decades interest in mitral valve regurgitation has increased as a result of the development of new technologies that have expanded the number of patients who can potentially benefit from mitral regurgitation treatments. To develop new devices for the treatment of mitral regurgitation, the focus has been placed on the functional anatomy and pathophysiology of the mitral valve, with the use of the most advanced methods of cardiac imaging that allow the best visualization of the mitral valve and a perfect understanding of the complexity of a specific disease. Mitral regurgitation is still underdiagnosed and undertreated in a substantial number of patients who have poor survival. Therefore, the priority should be to identify and treat these patients to increase their survival and quality of life. To achieve this goal, general physicians and cardiologists must be aware of all the treatment options that are currently available in dedicated centres of excellence. Patients referred to these centres can benefit from a tailored heart team-based approach. The aim of this Review is to analyse the basic principles of mitral regurgitation, discussing new concepts on the pathophysiology of the mitral valve that have been developed to facilitate the selection of patients for transcatheter procedures. We also describe the indications and timing of treatment, contemporary surgical and transcatheter techniques and the heart team approach, and highlight the need for centres of excellence.

Entities:  

Mesh:

Year:  2020        PMID: 32601465     DOI: 10.1038/s41569-020-0395-7

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  4 in total

1.  Transcatheter mitral valve intervention.

Authors:  Rea Ganatra; Robert Smith
Journal:  Br J Cardiol       Date:  2021-11-30

2.  Malignant Mitral Valve Prolapse: Risk and Prevention of Sudden Cardiac Death.

Authors:  Yasufumi Nagata; Philippe B Bertrand; Robert A Levine
Journal:  Curr Treat Options Cardiovasc Med       Date:  2022-03-22

3.  Percutaneous edge-to-edge repair of severe mitral regurgitation using the MitraClip XTR versus NTR system.

Authors:  Philipp M Doldi; Isabel Brinkmann; Mathias Orban; Lukas Stolz; Martin Orban; Thomas Stocker; Kornelia Loew; Joscha Buech; Michael Nabauer; Ben Illigens; Tiago Lemos Cerqueira; Timo Siepmann; Steffen Massberg; Joerg Hausleiter; Daniel Braun
Journal:  Clin Cardiol       Date:  2021-03-24       Impact factor: 2.882

4.  At the Crossroads of Minimally Invasive Mitral Valve Surgery-Benching Single Hospital Experience to a National Registry: A Plea for Risk Management Technology.

Authors:  Riccardo Cocchieri; Bertus van de Wetering; Sjoerd van Tuijl; Iman Mousavi; Robert Riezebos; Bastian de Mol
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.